Questions about data manipulation [GxP / QC / QA]

posted by qualityassurance – 2024-04-30 13:38 (49 d 02:51 ago) – Posting: # 23967
Views: 3,316

Dear Forum members,

❝ Dr. Anders Fuglsang has developed several software programs to detect such manipulation.


Is it advisable that CRO use this software (after implementing the SOP within the system) and prove that no such manipulation was done during BE study. By this way both sponsors and CROs are relaxed and regulatory authority will also have readily available data from the software.
The idea behind above approach is, there is no other way of finding such manipulation (profile duplication) during routine QA review or monitoring by sponsor.

Regards,
QA

Complete thread:

UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
84 visitors (0 registered, 84 guests [including 7 identified bots]).
Forum time: 16:30 CEST (Europe/Vienna)

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5